Gan & Lee Pharmaceuticals. (SHA:603087)

Market Cap	31.58B +5.8%
Revenue (ttm)	3.95B +13.7%
Net Income	1.02B +23.3%
EPS	1.73 +22.7%
Shares Out	595.20M
PE Ratio	30.62
Forward PE	20.56
Dividend	1.00 (1.88%)
Ex-Dividend Date	May 29, 2026

Volume	5,880,939
Open	53.24
Previous Close	53.18
Day's Range	52.34 - 53.79
52-Week Range	51.30 - 82.25
Beta	0.57
Analysts	Strong Buy
Price Target	77.00 (+45.15%)
Earnings Date	Aug 10, 2026

About SHA:603087

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1998
• Employees: 5,309
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603087

Financial Performance

In 2025, SHA:603087's revenue was 4.05 billion, an increase of 33.06% compared to the previous year's 3.05 billion. Earnings were 1.14 billion, an increase of 86.05%.